All News
This week money went towards more advanced rounds of financing for drugs and technology that have already shown a lot of promises.
Axsome hosted an investor day event to provide an update on plans for Sunosi and other developmental assets, including MDD treatment AXS-05.
New research by investigators at Columbia University and MIT describes how cancer cells often depend upon the importation of fat for continued growth and division.
A deadly fungus–Candida auris (C. auris)–has shaken up the biological world with its ability to reproduce sexually. What can be its dangers and what are the next steps? Know it all here.
“Science doesn’t care what markets are doing, and science moves forward,” ARCH Co-founder and Managing Director Robert Nelsen said in a statement.
Icosavax posted positive topline interim data from its Phase I/Ib trial of IVX-121, its candidate virus-like particle vaccine against the respiratory syncytial virus in young and older adults.
Generian and Mitobridge, a wholly-owned subsidiary of Astellas Pharma, announced a collaboration to discover and develop novel small molecules for undruggable therapeutic targets.
Voting 19-2, the Vaccines and Related Biological Products Advisory Committee favored redesigning booster shots to include the coronavirus’ Omicron variant.
The Phase III study of Jazz Pharmaceuticals cannabis-derived MS Sativex failed to achieve the primary endpoint of an improvement in muscle tone in patients.
Swiss biopharma giant Novartis plans to cut up to 8,000 jobs in hopes of saving at least $1 billion by 2024.
Biogen’s Chirfi Guindo discusses the launch of the company’s next-generation approach to teaching STEM to even more students, leading to potential careers in the field.
BioSpace spoke with several Black individuals working within the life sciences to get their thoughts on the current representative disconnect and what they believe can be done to fix it.
Roivant Sciences announced it has discontinued development of several assets following a pipeline reprioritization.
Ascletis has commenced its Phase II trial in China for its candidate drug ASC22 alongside anti-retroviral therapy for the functional cure and immune restoration of HIV-1 infection.
Boehringer and BiomX intend to use the discovery platform to identify biomarkers for a pathogenic bacterium thought to be associated with IBD.
Pearl Huang, Ph.D, has been appointed the CEO of U.K.-based Dunad Therapeutics, a Novartis-backed biopharmaceutical startup.
Kezar Life Sciences stock rose 92% after it announced positive topline results from its Phase II clinical trial investigating the use of zetomipzomib for the treatment of Lupus Nephritis (LN).
The findings, presented during a poster session at the EASL 2022 International Liver Congress, revealed that of the 407 D-LIVR participants, nearly 30% developed liver cirrhosis.
Pfizer and Roivant unveiled Priovant Therapeutics to develop and market new therapies for a wide range of autoimmune diseases with high mortality and morbidity rates.
Astellas Pharma and Sutro Biopharma inked a global collaboration and licensing deal to work to discover and develop novel immunostimulatory antibody-drug conjugates.